Patent Board Urged In New Petition To Cancel UPenn T-Cell Technology

(April 12, 2022, 12:07 PM EDT) -- ALEXANDRIA, Va. — In a petition for inter partes review (IPR) filed April 12, a biopharmaceutical company and its subsidiary maintain a patent claiming an “anti-tumor effective amount” of chimeric antigen...
To view the full article, register now.